Analysts think EDIT stock price could increase by 237%
Dec 26, 2024, 12:25 PM
14.05%
What does EDIT do
Editas Medicine, headquartered in Cambridge, Massachusetts, specializes in genome editing technology and developed a proprietary CRISPR-based platform for transformative genomic medicines. Its lead program, reni-cel, aims to treat sickle cell disease and beta thalassemia.
13 analysts think EDIT stock price will increase by 237.19%. The current median analyst target is $4.08 compared to a current stock price of $1.21. The lowest analysts target is $1.01 and the highest analyst target is $10.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
